Effect of turmeric on myoclonic seizure

Evaluation of therapeutic effects of Active ingredient of turmeric (Curcumin) on the treatment of children with myoclonic epilepsy

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2014121020266N1

Enrollment

Registered

2015-01-14

Start date

2014-11-19

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myoclonic seizure. Myoclonic epilepsy

Interventions

Patients’ in intervention group: children aged between 3 months and 14 years who suffer from myoclonic epilepsy, with at least five seizure attacks daily despite medications. Exclusion criteria includ

Treatment - Drugs

Eligibility

Sex/Gender

All

Age

3 Months to 14 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: children from 3 month to 14 years old; children with myoclonic seizure and spasm; children with rear seizure. Exclusion criteria: children with underlying diseases(cardiac, renal, hepatic,...); children with growth malformation.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Numbet of seizure in 24 h. Timepoint: Daily. Method of measurement: Parents' report.	—

Secondary

Measure	Time frame
Liver, renal and hematologic side effects. Timepoint: Before and after curcumin and placebo advising. Method of measurement: Blood sampeling.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactKazem Hassanpour

Mashhad University of Medical Sciences

hasanpourk921@mums.ac.ir+98 51 3801 2540

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026